Company intelligence / Profile preview

NineteenGale Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

NineteenGale Therapeutics is a joint venture between NeuroTheryX and Cyclica, focusing on the discovery and development of next-generation cannabinoid-inspired therapeutics for neuropsychiatric and neurological disorders. The company combines NeuroTheryX's phenotype-based drug discovery platform with Cyclica's AI-augmented Ligand Express and Ligand Design platforms to identify and advance novel molecular entities. Early molecules have shown promising in vitro and in vivo data, though no clinical trial results are publicly available yet.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

NeuroTheryXCyclica

Beyond the preview

Go deeper on NineteenGale Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NineteenGale Therapeutics.

Explore the full profile